CSR News_ESG_Fosun Pharma

We are committed to sustainable growth in both talent and products,
and contribute to the health and well-being of humanity through continuous innovation and equitable healthcare access.

2025-04-07

Fosun Pharma Announces 2024 ESG and Sustainability Report: Continuous Innovation for the Sustainable Development of Inclusive Healthcare

More
2024-03-27

Fosun Pharma Releases Its First ESG and Sustainability Report Deepening ESG Practice and Driving Sustainable Development Through Innovation

More
2023-09-25

Caring for Women: Shanghai-Yunnan Cooperation to Enhance Primary Healthcare Standards Fosun Pharma and the Shanghai Soong Ching Ling Foundation Launch the Pink & Blue Ribbon Public Welfare Campaign for Cervical and Breast Cancer Screening at Xishuangbanna

More
2023-04-26

Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative

More
2023-03-29

Fosun Pharma’s 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public

More
2022-10-14

Fosun Pharma’s MSCI ESG Rating Upgraded to A

More
2020-12-23

STARBUDS program initiated to provide life-cycle care for children with rare diseases

More
2020-12-09

Fosun Pharma granted two ESG awards for continued efforts in ESG management

More
2020-12-04

Fosun Pharma granted “GoldenBee Excellent CSR Report 2020 – Evergreen Award”

More

Total：110 Home Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last The Number Of Pages：1/13 GO

Kaiyun·开云

开云(中国)Kaiyun·体育官方网站 - 登录入口 | APP下载

Our Company

Our Business

R&D

ESG

Investor Relations

News

Careers

Fosun Pharma Announces 2024 ESG and Sustainability Report: Continuous Innovation for the Sustainable Development of Inclusive Healthcare

Fosun Pharma Releases Its First ESG and Sustainability Report Deepening ESG Practice and Driving Sustainable Development Through Innovation

Caring for Women: Shanghai-Yunnan Cooperation to Enhance Primary Healthcare Standards Fosun Pharma and the Shanghai Soong Ching Ling Foundation Launch the Pink & Blue Ribbon Public Welfare Campaign for Cervical and Breast Cancer Screening at Xishuangbanna

Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative

Fosun Pharma’s 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public

Fosun Pharma’s MSCI ESG Rating Upgraded to A

STARBUDS program initiated to provide life-cycle care for children with rare diseases

Fosun Pharma granted two ESG awards for continued efforts in ESG management

Fosun Pharma granted “GoldenBee Excellent CSR Report 2020 – Evergreen Award”